© 2026 Nanjing Finechem Holdings Co., Ltd,
All Right Reserved
Science often moves one careful step at a time, but some inventions change how researchers work across the world. Fluorescent labeling, especially fluorescent antibodies, has meant clearer answers in research labs and hospitals. Anti-Human IgG conjugated to FITC (fluorescein isothiocyanate) stands among those mainstays that scientists have learned to trust with their most critical immunoassays. This journey began decades ago when Albert Coons showed that antibodies could be detected by attaching a fluorescent dye. The green light of FITC in particular became something familiar in immunology labs, driving a revolution in diagnostics and the understanding of how human immune defenses respond. Standards for these reagents did not appear overnight. Persistent work, driven by curiosity and real-world needs, shaped how today’s Anti-Human IgG FITC is made and used.
Every bottle of Anti-Human IgG FITC carries a blend of biology and chemistry. At its heart sits an antibody tuned to catch human immunoglobulin G. Scientists bind FITC to the antibody, giving it the power to glow under the right light. FITC isn’t just a simple colorant—it’s a classic green fluorophore that absorbs blue light and emits green, with excitation around 494 nanometers and emission at about 520 nanometers. Anti-Human IgG FITC usually arrives as a protein solution, made with care to ensure stability. Each batch faces consistency challenges, since protein-based reagents can degrade or clump up over time. Useful reagents balance brightness with clarity—too many dye molecules on each antibody block binding, too few dim the signal. The chemistry runs deep: FITC attaches through its isothiocyanate group, reacting with lysine amino acids on the antibody surface. This reaction looks simple on paper, but the real world needs precise control to keep the antibodies active and the fluorescence sharp.
In practice, no researcher ignores the label on a vial. Clear labeling and reliable technical details save hours of troubleshooting. In the case of Anti-Human IgG FITC, important factors include antibody concentration, the antibody subclass, dye-to-protein ratio (often indicated as the F/P ratio), buffer composition, and shelf life. Even the smallest drift outside of the optimal F/P ratio can mean the difference between results and confusion. To keep reagents useful, manufacturers stabilize the solution, often with proteins like BSA or preservatives to block bacteria. The best suppliers provide batch-specific details—for good reason, since reproducibility sometimes hangs by a thread. For applications ranging from basic research to advanced clinical flow cytometry, any misstep in storing or handling these reagents can mean data that no one can trust.
Creating Anti-Human IgG FITC isn’t just about mixing two ingredients. There’s a choreography to preparing the conjugate. Scientists purify antibodies raised against human IgG, making sure the final product has a known, clean specificity. FITC, usually dissolved in a suitable solvent, reacts with the antibody under controlled pH and temperature. After the coupling, extra free dye must vanish—often washed away through dialysis or gel filtration. The process continues with careful testing; any batch that fails the sensitivity or specificity tests never sees a research bench. In years spent at the lab bench, I’ve watched more than one project slow down because a flawed antibody conjugate left us with fuzzy data and wasted effort. Over time, seeing the difference between a well-made vs. poorly-made reagent builds a kind of craftsman’s respect for those careful steps that never show up in the method section of published papers.
Every lab hand knows fluorescent chemicals deserve respect. FITC has been in labs for nearly a century, but good work habits always matter. FITC itself is reactive, sometimes causing skin sensitization, so gloves and proper protection remain the rule. Antibody solutions use preservatives like sodium azide, which can be toxic. Risk doesn’t mean avoiding use—just taking steps to protect yourself and others in the room. This means not snacking at the bench and following protocols for spills. Teams need training. I’ve seen that the real danger comes from taking shortcuts, not the reagent itself. Smart habits, clear labeling, and staying sharp day to day matter more than any written warning. Researchers must count on each other to keep labs safe and productive.
Researchers turn to Anti-Human IgG FITC for more than one reason. In classic immunofluorescence, this reagent helps pinpoint where antibodies are binding in tissues, showing up under a standard fluorescence microscope as bright green. In hospitals, pathologists use Anti-Human IgG FITC to diagnose autoimmune diseases or kidney issues, looking at how and where human antibodies deposit inside organs. Flow cytometry draws heavily upon this reagent, giving quick counts of immune cell populations in blood samples. This isn’t just for inquiry’s sake: clinical laboratories use FITC-conjugated antibodies for everything from tracking therapy progress to gauging immune deficiencies. Each application asks something slightly different from the reagent—robust brightness, low background, or the right subclass specificity. It’s impressive to watch a single bottle open up so many research and clinical possibilities in hands both experienced and new.
Using FITC-based reagents comes with built-in tradeoffs. FITC’s fluorescence isn’t the brightest or most stable on the market; prolonged exposure to light makes the signal fade. That’s frustrated more than one young scientist who didn’t cover their slides or samples. FITC works well for single-color labeling but can sometimes bleed into neighboring detection channels in complex panels. Another concern lies with non-specific binding; every run needs controls to sort real signals from background noise. There’s a science and art to troubleshooting false positives, and years of shared troubleshooting stories fill countless lab notebooks. Each new kit or reagent iteration tries to cut down these persistent nuisances, but practice and care still play the biggest roles.
The story of Anti-Human IgG FITC isn’t finished. Newer dyes and conjugation chemistries promise higher brightness, lower background, and better multiplexing. Yet this workhorse stays present in core facilities and teaching labs, a testament to its utility and the steady discipline of those who refine it. The research community calls for greener, safer dyes, more standardized conjugation methods, and tighter specificity—all to deliver clearer, faster answers in both discovery and diagnostics. As genomics and proteomics churn out data, the need for simple, direct visualization and detection tools like Anti-Human IgG FITC hasn’t faded. It stands as a reminder: progress in science means balancing tradition and innovation, keeping both curiosity and caution alive at the bench.
Toxicity studies on FITC and antibody conjugates guide lab users to safer practices. Studies have shown that, while FITC itself is not acutely dangerous in trace research amounts, routine and careless exposure can lead to skin or respiratory problems. Research evaluating the environmental impact and breakdown products of FITC in water raises concerns about long-term waste disposal. Labs often collect excess or expired reagents in proper chemical waste to limit this exposure. The same goes for understanding the preservatives used; sodium azide, often present, can interfere with water treatment and is hazardous on contact. From my own years handling these reagents, I’ve learned that clear protocols, proper labeling, and up-to-date safety training offer the best shield against risks. The rare emergencies I witnessed—fits of coughing after a spill, surprise skin irritation—always traced back to lapses in attention or protocol, never the base chemistry itself.
As technology surges ahead, Anti-Human IgG FITC adapts along with it. Excitement in diagnostics now leans toward multiparameter flow cytometry, spectral imaging, and digital pathology. Yet, few new tools arrive as tried-and-true as this classic conjugate. The quest for brighter, more stable fluorophores, and more specific detection reagents means a crowded marketplace, but Anti-Human IgG FITC continues to anchor the field. Its broad recognition, cost-effectiveness, and predictable behavior keep it a staple even as companies roll out synthetic dyes and quantum dots. Future research may see it paired with artificial intelligence readouts, integrated into low-resource diagnostic kits, or reimagined for automated platforms that demand ever-higher reliability. Those changes won’t erase the need for skilled hands, care for the process, and realistic respect for what fluorescence-based detection can and cannot promise. With each advance, science doesn’t throw out its old roots—it builds on them, much like researchers continue to reach for bright-green Anti-Human IgG FITC bottles, confident in its role bridging generations of discovery.
Anti-Human IgG FITC plays a specific role in lab work. Lab professionals use it to spot and analyze human antibodies, those Y-shaped proteins that help tame infections. “IgG” stands for immunoglobulin G, a main player in the immune system. FITC, short for fluorescein isothiocyanate, is a dye that glows under certain light. Attach this dye to the antibody and scientists can see where antibodies are present in cells or tissues — a key advantage in both research and diagnostics.
Day-to-day, this tool turns up in techniques like flow cytometry and immunofluorescence microscopy. Picture a set of cells, some infected, some not. By tagging IgG with FITC, researchers spot the infected cells with a bright green flash under the microscope. This helps map out infections and guides decisions in everything from academic studies to clinical labs.
In my own time in academic labs, staining experiments using FITC-linked antibodies saved hours. Instead of complicated chemical reactions that faded quickly, a single dab of Anti-Human IgG FITC outlined the details. It’s a relief when an experiment just works, and clear results drive progress. Colleagues in clinical labs have told me how the same dye simplifies diagnosis tasks, helping catch diseases earlier by lighting them up on slides.
Detecting antibodies means more than just glowing dots in a picture. Finding the right pattern can suggest an autoimmune disease, an infection, or a reaction to a treatment. Take lupus: certain autoantibodies flag up only with clear lab methods. With Anti-Human IgG FITC, clinicians get answers faster and with more confidence, reducing wait times for patients.
Developing treatments has grown more precise as well. Vaccine manufacturers track whether people build strong enough antibody responses. HIV research depends on seeing how antibodies latch onto the virus — data made possible by reliable staining tools. In cancer, doctors follow immune responses to new therapies, making treatment decisions in real-time. It is hard to imagine modern antibody research running effectively without this kind of detection chemistry.
Some bumps do exist. FITC dyes can fade or “photobleach” under the microscope, softening their glow over time. This means that results depend on careful technique and good equipment. Scientists swap out older microscopes with better optics or move to newer, more stable dyes when budgets allow. Suppliers work on tweaks, aiming for versions that shine longer and brighter.
Non-specific staining can be a headache, especially in messy human samples. Extra washing steps and improved antibody blocking recipes cut down this glare. Documentation and solid lab training turn out to be just as important as the fancy equipment, keeping errors in check and results reliable.
A good tool in science means traceability and proven safety. Reputable suppliers follow strict standards for antibodies and dyes, sharing data about how each batch performs. In the age of open science, labs lean on published protocols and peer-reviewed controls. Robust evidence, hands-on skill, and continual quality checks together build lasting confidence in results seen with Anti-Human IgG FITC.
Lab life rarely leaves room for error, especially with something as familar as Anti-Human IgG FITC. Anyone who’s tried to guess at dilutions soon learns the hard way. Staining gets messy, signal looks weird, or the background glows loud enough to drown out real data. FITC conjugates aren’t cheap. Antibody waste doesn’t just hurt budgets; it slows down projects and eats up resources. That’s why plenty of old-school researchers still look for the “sweet spot” rather than follow the bottle strictly.
Most antibody data sheets recommend starting dilutions between 1:50 and 1:200 for flow cytometry. Immunofluorescence often lands in the 1:100 to 1:500 range. Lot-to-lot variation happens, even within reliable brands. During my own projects, I’ve found a 1:100 dilution works well for Jurkat or PBMCs, especially after careful titration. Some samples benefit from 1:200 or even 1:400, depending on cell number or fluorescence background. Pretending one recipe suits every setup ignores basic science. Even water quality and pipette technique shape the outcome. There’s a reason so many researchers set aside an afternoon just to titrate.
Signal intensity varies with the quality of the cells. Some people forget to Fc block, and non-specific binding can spike out of control. I once skipped that step on a late Friday, eager to finish early, and ruined a whole experiment. Over-concentration makes negatives brighter than positives. Under-dilution leads to fuzzy, even unreadable plots. FITC suffers from photobleaching more than many dyes. People who leave plates under the microscope too long pay for it with lost data.
Getting the buffer right keeps the antibody happy. PBS with a hint of BSA keeps background down, and sodium azide can preserve samples if things slow down. Pipetting accuracy really gets tested at small dilutions — even experienced hands double-check their volumes. Consistency counts more than following a textbook protocol. Most people track the number of cells closely. For me, I stick to 1 million per tube, but some colleagues swear by adjusting for higher or lower concentrations depending on the day’s goal.
Few labs share exact numbers in their papers, but the best ones explain their titration results. A solid titration graph tells the story clearer than any methods section. Modern labs run preliminary tests with serial dilutions and find the minimal concentration that gives a tight, bright signal for positive cells, while negatives stay quiet. That’s not just best practice — it prevents mixed-up data and time-consuming repeats. Personally, I suggest saving every titration chart, even if just for your own records. The next big experiment may run smoother for it.
Documentation matters. Jotting down every dilution, buffer mix, and cell count helps spot trends early. A colleague once noticed the same lot of antibody drifting over a few weeks and fixed it before running dozens of patient samples. Regular review and calibration of pipettes keep technique sharp. Group meetings that discuss protocol tweaks help everyone get better. Suppliers could do more, too — better lot-to-lot consistency, clearer storage guidelines, and fresher FITC conjugates would all help. For now, the best solution is careful setup, regular titration, and honest data tracking. Those habits deliver reproducible results, save time, and keep budgets in check.
Researchers rely on antibodies like Anti-Human IgG FITC for flow cytometry and immunofluorescence imaging. These fluorescent conjugates amplify tiny signals and light up cellular worlds invisible to the naked eye. I’ve seen good results quickly unravel because a reagent slipped out of its storage range after a power outage or poor fridge maintenance. Each molecule in that vial carries a job, and losing fluorescence cuts down on signal and data accuracy. That’s not just an inconvenience; it's lost time, missed discoveries, and extra cost.
Heat, light, and microbial contamination are real threats to fluorescein-labeled antibodies. FITC, the attached fluorescent label, doesn’t rebound after exposure to broad-spectrum light. Suddenly, an expensive antibody turns dim and nearly useless, just from sitting too long under lab lights or an open freezer door. My early lab years taught the painful lesson—leave an antibody on the benchtop “for a minute” and you risk ruining an entire experiment.
Manufacturers and published data agree on clear steps: store Anti-Human IgG FITC at 2-8°C. This range helps slow down degradation and preserves activity. No freezing, unless you know with certainty the antibody tolerates it, since freeze-thaw cycles can quickly wreck protein structure. I’ve seen inconsistent bands on a gel appear, just because a colleague didn’t follow the temperature guidelines. Those simple degrees make all the difference over weeks and months.
Light-blocking is crucial. Use amber or light-opaque tubes, not just because it sounds smart but because UV and visible light fade FITC’s glow rapidly. Shielding from light extends shelf life and simplifies troubleshooting later. An old friend who spent years in diagnostic labs never let a sample tube see open-air lighting, and as a result, his work rarely faced unexplained drop-offs in signal.
Contamination often sneaks in during careless pipetting or when caps stay open too long. Bacteria or fungi thrive in protein-rich solutions and they won’t politely skip your antibody stocks. Using sterile tips, keeping bottles tightly capped, and working quickly on ice pays off—these steps kept reagents fresh beyond their stated expiration in tight-budget labs I’ve worked in. Centrifuging vials before opening minimizes floating particles that might clog your flow cytometer or cause background staining.
Every lab should track batch numbers and receiving dates. A notebook or digital log helps catch storage mistakes early and flags drops in performance. If someone else in the building has an issue with the same lot, early warning lets the team act fast. In a core facility I helped manage, tracking flagged one storage fridge that ran hot for months, saving the other stocks from the same fate.
Labs run on fragile resources. The price of a replacement vial stings, but lost data or repeat runs hurt more. Following strict storage specs for Anti-Human IgG FITC gives every experiment the best chance. That singular focus on careful handling and attentive storage—backed up by plenty of published guidance—keeps labs productive and protects the investment that every research step represents.
There’s a lot riding on picking the right antibody for research projects. Those little green-labeled vials in the fridge, like Anti-Human IgG FITC, can make or break experiments, especially when the costs keep climbing. Many folks wonder: what really happens if you use an antibody labeled “anti-human” in experiments with animal samples? I’ve seen plenty of colleagues take this shortcut. Maybe they’re working with monkey tissue, or maybe it’s dog, rabbit, or mouse. The temptation sits there—a hope to save time or money. Does anti-human IgG FITC stick to more than just human targets?
IgG, or immunoglobulin G, shows up in all mammals, but the structure shifts from species to species. FITC just gives the glowing signal, but the real trick is in the antibody part. Some folks assume antibodies labeled as “anti-human” won’t recognize much except human samples. I’ve watched enough failed experiments to know that’s wishful thinking. Studies from as far back as the 1980s spell out the risk: secondary antibodies raised against human IgG can, and do, latch on to IgG molecules from apes, monkeys, and even other mammals, though not always with the same strength. Sometimes, even the supplier’s data sheet admits it—cross-reactivity creeps in with non-human primates, guinea pigs, rabbits, cows, and other mammals.
The root of the issue often comes down to how close the protein sequence looks. Human and monkey IgG molecules barely differ, so it makes sense to expect overlap. I had a project in grad school with baboon samples. Someone tried cutting corners with anti-human IgG; the results came out muddy, with fluorescent signals everywhere. It turned out, the secondary antibody tagged both the expected target and unrelated proteins. False positives cause confusion, and precious samples get wasted while we troubleshoot for days.
People trust research findings to push medical science forward and guide clinical decisions. Messy data from cross-reactive antibodies can cloud results in zoonotic disease research, vaccine development, or diagnostics. For example, coronavirus studies often use animal models, yet even subtle antibody cross-reactions will throw off ELISA results or flow cytometry. Weak specificity means researchers risk reporting data that don’t actually reflect what’s happening in humans—skewed results can ripple through publications and clinical pipelines.
The science community values accuracy and integrity. If an experiment depends on a species-specific result, using a secondary antibody validated just for that species helps more than any shortcut. Many vendors now share detailed cross-reactivity charts, and journals refuse to publish research without proper controls. I recommend running a “no primary” or “no antigen” control every time—waste of time, some say, but the peace of mind is worth it. For critical projects, researchers should seek out antibodies that have been affinity-purified and adsorbed to remove cross-reactivities.
Antibody validation also deserves more attention when budgets allow. Antibodies get batch-tested on panels of different species’ sera, and vendors are starting to put this effort front and center. Peer pressure inside labs helps too; if everyone on a team double-checks antibody choices and documentation, mistakes are less likely. I’ve found that clear communication with suppliers, and even in-house pilot testing, saves trouble down the line. Trusting a label on a bottle without digging deeper rarely pans out.
The world needs scientific progress built on trust. Careful antibody selection, species matching, tough controls, and validation may sound like extra steps, but they keep the science solid. That’s something every researcher owes not just to themselves, but also to the wider community that relies on these results.
A lot of folks working in research hit a wall when they face questions about fluorochromes like FITC. Simple curiosity sparks it: “What’s the excitation and emission wavelength for FITC in this product?” Looking at the labels, most will find answers somewhere in the datasheet. Yet the numbers on a page don't always tell the story behind why these wavelengths matter so much or how they affect the results downstream.
FITC, or fluorescein isothiocyanate, floats as one of the first dyes many scientists use. In any standard setting, FITC lights up under blue light around 488 nanometers—that’s its excitation wavelength. It gives off a greenish light people see most strongly around 520 nanometers—that’s the emission wavelength. Having spent hours hunched over a flow cytometer, these numbers become more than facts. If the instrument drifts outside those wavelengths, the data veer off, too. Nothing shakes confidence in results like a filter mismatch, leading to background noise or lost signal.
Trust in FITC comes from how tightly those excitation and emission peaks perform across companies. Whether running antibody staining for immunofluorescence, sorting cells, or reading a western blot, these wavelengths stay reliable. There’s plenty of peer-reviewed backup. A study from Nature Methods (2008) remains my go-to: FITC still lands at 488 nm excitation and 520 nm emission in most commercial products—right where the datasheet says. The numbers did not drift across different labs, and those same ranges help compare protocols across platforms.
Before jumping in, it pays off to check that a system’s filters match the dye’s properties. Many times, using a filter that’s off by 10 or 20 nanometers swallows up the signal or piles on false positives. As a result, asking for precise excitation and emission details isn’t just splitting hairs; it stops wasted time and short circuits troubleshooting later. Companies now print this info clearly, but double-checking never hurt.
Folks who want reproducible science need more than numbers on a datasheet. I have seen antibodies labeled as "FITC," only to find that some batches carried impurities. Minor tweaks in the dye’s chemical structure can tug on those critical wavelengths, pulling the signal off its regular spot. Labs using older or off-brand filters often stumble over faint results or ghost signals. In one lab I worked at, unexpected bleed-through from FITC forced redesign of panels and ate up valuable samples. Good practice means confirming the dye lot and clean source, then testing with controls on hand.
Sturdy controls make a world of difference. Using a single-color control, matched to the exact FITC lot and product, roots out filtering issues early. Many research groups save time by calibrating flow cytometers and microscopes with FITC-conjugates from a trusted lot before running precious samples. It saves headache later and builds confidence in the findings. Companies and researchers can also chip in by reporting issues with wavelength drift or impurities, helping guide improvements in manufacturing and transparency.
Those wavelengths—488 for excitation and 520 for emission—anchor experiments beyond one lab or protocol. Bringing in new products? Ask questions, check the specs, and run controls up front. Good habits there keep the science honest and the data strong, even as new fluorescent dyes expand the toolbox. Through careful inspection and collaboration, each result tells a story worth trusting.
| Names | |
| Preferred IUPAC name | Immunoglobulin G, human, antibody fluorescein isothiocyanate conjugate |
| Other names |
Goat Anti-Human IgG (FITC) FITC-conjugated Anti-Human IgG Anti-Human Immunoglobulin G FITC |
| Pronunciation | /ˈæn.taɪ ˈhjuː.mən aɪ.dʒiːˈdʒiː ˌɛf.aɪ.tiːˈsiː/ |
| Identifiers | |
| CAS Number | 56933-56-9 |
| Beilstein Reference | 3917216 |
| ChEBI | CHEBI:37683 |
| ChEMBL | CHEMBL2108831 |
| ChemSpider | No ChemSpider |
| DrugBank | DB00028 |
| ECHA InfoCard | 03c2e7e428 |
| EC Number | F0202 |
| Gmelin Reference | 39745 |
| KEGG | NA |
| MeSH | Immunoglobulin G |
| PubChem CID | 16211231 |
| RTECS number | VX3020000 |
| UNII | DFK72QQQ55 |
| UN number | UN3373 |
| CompTox Dashboard (EPA) | CompTox Dashboard (EPA): "DTXSID4047270 |
| Properties | |
| Chemical formula | C1365H2102N364O393S6 |
| Molar mass | ~150 kDa |
| Appearance | Appearance: "Clear, colorless to slightly yellow solution |
| Odor | Characteristic |
| Density | 1 mg/mL |
| Solubility in water | soluble in water |
| log P | 2.8 |
| Vapor pressure | Negligible |
| Basicity (pKb) | 9.31 |
| Refractive index (nD) | 1.017 |
| Viscosity | Low viscosity |
| Dipole moment | 13.17 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 164 J/(mol·K) |
| Pharmacology | |
| ATC code | V04CL02 |
| Hazards | |
| Main hazards | H317: May cause an allergic skin reaction. |
| GHS labelling | GHS02, GHS07 |
| Pictograms | GHS07, GHS08 |
| Signal word | Warning |
| Hazard statements | H317: May cause an allergic skin reaction. |
| Precautionary statements | P261, P263, P280, P302+P352, P305+P351+P338, P337+P313 |
| NIOSH | 11-401 |
| REL (Recommended) | 10-20 µL per 10⁶ cells |
| Related compounds | |
| Related compounds |
Goat Anti-Human IgG (H+L) FITC Mouse Anti-Human IgG FITC Rabbit Anti-Human IgG FITC Anti-Human IgG PE Anti-Human IgG APC Anti-Human IgG Alexa Fluor 488 Anti-Human IgG HRP Anti-Human IgG Biotin |
